Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events

Abstract Ductal carcinoma in situ (DCIS) incidence has risen rapidly with the introduction of screening mammography, yet it is unclear who benefits from both the amount and type of adjuvant treatment (radiation therapy, endocrine therapy) versus what constitutes over-treatment. Our goal was to ident...

Full description

Saved in:
Bibliographic Details
Main Authors: Thomas J. O’Keefe, Christina Yau, Emma Iaconetti, Eliza Jeong, Case Brabham, Paul Kim, Joseph McGuire, Ann Griffin, Anne M. Wallace, Laura J. Esserman, Olivier Harismendy, Gillian L. Hirst
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-025-00774-3
Tags: Add Tag
No Tags, Be the first to tag this record!